136 related articles for article (PubMed ID: 29982502)
1. Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes.
Tresman R; Goldenberg SD
J Antimicrob Chemother; 2018 Oct; 73(10):2851-2855. PubMed ID: 29982502
[TBL] [Abstract][Full Text] [Related]
2. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.
Wilcox MH; Ahir H; Coia JE; Dodgson A; Hopkins S; Llewelyn MJ; Settle C; Mclain-Smith S; Marcella SW
J Antimicrob Chemother; 2017 Sep; 72(9):2647-2656. PubMed ID: 28633368
[TBL] [Abstract][Full Text] [Related]
3. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.
Zhang D; Prabhu VS; Marcella SW
Clin Infect Dis; 2018 Apr; 66(9):1326-1332. PubMed ID: 29360950
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
5. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study.
Dinh A; Le Monnier A; Emery C; Alami S; Torreton É; Duburcq A; Barbier F
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1297-1305. PubMed ID: 30941532
[TBL] [Abstract][Full Text] [Related]
6. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
Kunishima H; Ito K; Laurent T; Abe M
J Infect Chemother; 2018 Nov; 24(11):892-901. PubMed ID: 30190105
[TBL] [Abstract][Full Text] [Related]
7. Health care resource utilization and costs of recurrent
Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
[No Abstract] [Full Text] [Related]
8. Excess length of hospital stay, mortality and cost attributable to
Kimura T; Stanhope S; Sugitani T
Epidemiol Infect; 2020 Mar; 148():e65. PubMed ID: 32115019
[TBL] [Abstract][Full Text] [Related]
9. Recurrent Clostridium difficile infection in intensive care unit patients.
Jasiak NM; Alaniz C; Rao K; Veltman K; Nagel JL
Am J Infect Control; 2016 Jan; 44(1):36-40. PubMed ID: 26432184
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.
Shah DN; Aitken SL; Barragan LF; Bozorgui S; Goddu S; Navarro ME; Xie Y; DuPont HL; Garey KW
J Hosp Infect; 2016 Jul; 93(3):286-9. PubMed ID: 27209056
[TBL] [Abstract][Full Text] [Related]
11. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles.
Allegretti JR; Kearney S; Li N; Bogart E; Bullock K; Gerber GK; Bry L; Clish CB; Alm E; Korzenik JR
Aliment Pharmacol Ther; 2016 Jun; 43(11):1142-53. PubMed ID: 27086647
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.
Bouza E; Cobo J; Rodríguez-Hernández MJ; Salavert M; Horcajada JP; Iribarren JA; Obi E; Lozano V; Maratia S; Cuesta M; Uría E; Limón E
Rev Esp Quimioter; 2021 Apr; 34(2):126-135. PubMed ID: 33618513
[TBL] [Abstract][Full Text] [Related]
13. Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults.
Feuerstadt P; Nelson WW; Drozd EM; Dreyfus J; Dahdal DN; Wong AC; Mohammadi I; Teigland C; Amin A
J Am Med Dir Assoc; 2022 Oct; 23(10):1721-1728.e19. PubMed ID: 35288083
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of fixed and variable hospital costs due to Clostridium difficile infection: institutional incentives and directions for future research.
Ryan P; Skally M; Duffy F; Farrelly M; Gaughan L; Flood P; McFadden E; Fitzpatrick F
J Hosp Infect; 2017 Apr; 95(4):415-420. PubMed ID: 28320542
[TBL] [Abstract][Full Text] [Related]
15. Attributable costs and length of stay of hospital-acquired
Leal JR; Conly J; Weaver R; Wick J; Henderson EA; Manns B; Ronksley P
Infect Control Hosp Epidemiol; 2019 Oct; 40(10):1135-1143. PubMed ID: 31342884
[TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.
Rodrigues R; Barber GE; Ananthakrishnan AN
Infect Control Hosp Epidemiol; 2017 Feb; 38(2):196-202. PubMed ID: 27817758
[TBL] [Abstract][Full Text] [Related]
17. The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study.
Asensio A; Di Bella S; Lo Vecchio A; Grau S; Hart WM; Isidoro B; Scotto R; Petrosillo N; Watt M; Nazir J
Int J Infect Dis; 2015 Jul; 36():31-8. PubMed ID: 26003403
[TBL] [Abstract][Full Text] [Related]
18. Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan.
Fukuda H; Yano T; Shimono N
Pharmacoeconomics; 2018 Nov; 36(11):1367-1376. PubMed ID: 30022364
[TBL] [Abstract][Full Text] [Related]
19. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review.
Gabriel L; Beriot-Mathiot A
J Hosp Infect; 2014 Sep; 88(1):12-21. PubMed ID: 24996516
[TBL] [Abstract][Full Text] [Related]
20. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study.
Zhang S; Palazuelos-Munoz S; Balsells EM; Nair H; Chit A; Kyaw MH
BMC Infect Dis; 2016 Aug; 16(1):447. PubMed ID: 27562241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
